FDA
-
-
-
-
-
-
-
FDA grants Breakthrough Therapy status to Novartis ianalumab for Sjögren's
-
-
-
-
-
-
-
Novartis receives FDA approval for oral CSU treatment Rhapsido
-
-
-
-
-
-
-
Novartis receives third FDA approval for oral Fabhalta
-
-
-
-
-
-
-
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
-
-
-
-
-
-
-
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
-
-
-
-
-
-
-
New Novartis (NVS) Fabhalta data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgAN
-
-
-
-
-
-
-
MorphoSys AG (MOR) to be Acquired by Novartis for EUR 2.7B Equity Value
-
328,607 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

